Citation

Kim AP, Baker DE. Hosp. Pharm. 2016; 51(11): 928-939.

Copyright

(Copyright © 2016, Thomas Land Publishers)

DOI

10.1310/hpj5111-928

PMID

unavailable

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The December 2016 monograph topics are ozenoxacin cream, ocrelizumab, naldemedine, eteplirsen, and abaloparatide. The Safety MUE is on buprenorphine buccal. 2016 © Thomas Land Publishers, Inc.

Language: en

Keywords

human; Review; suicidal ideation; depression; suicide attempt; virus infection; headache; practice guideline; drug mechanism; influenza; drug safety; placebo; drug fatality; drug efficacy; fever; prophylaxis; bronchitis; rash; relapse; side effect; psoriasis; flu like syndrome; pharyngitis; drug contraindication; drug monitoring; drug indication; dermatitis; multiple sclerosis; angioneurotic edema; drug dose regimen; urticaria; acute graft rejection; urinary tract infection; beta1a interferon; glatiramer; injection site reaction; anaphylaxis; injection site pain; eczema; upper respiratory tract infection; interferon beta serine; lymphadenopathy; herpes simplex; rhinopharyngitis; randomized controlled trial (topic); abnormal laboratory result; daclizumab; multicenter study (topic); hypertransaminasemia; phase 3 clinical trial (topic); clinical outcome; oropharynx pain